07:00 , Apr 5, 2012 |  BC Innovations  |  Targets & Mechanisms

AML takes LSD1

Two teams have independently provided preclinical proof of concept for using lysine-specific histone demethylase 1 inhibitors to treat acute myelogenous leukemia. 1,2 One of the teams is now running a clinical trial of a generic...
07:00 , Jul 6, 2009 |  BC Week In Review  |  Company News

Progen, Global TransBiotech Inc., KAI Pharmaceuticals Inc deal

Progen disclosed that Global TransBiotech is the company to which it licensed exclusive, worldwide rights to develop and commercialize muparfostat (formerly PI-88 ). Progen announced the deal in May. Global TransBiotech will focus on development...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Clinical News

PG11047: Phase I restarted

Progen restarted an open-label, dose-escalation, U.S. Phase I (47-01-002) trial evaluating PG11047 in combination with various marketed drugs in up to 126 patients. CellGate Inc., which was acquired by Progen in February, had enrolled 66...
07:00 , May 19, 2008 |  BC Week In Review  |  Clinical News

PG-11047: Phase I restarted

Progen restarted a dose-escalation Phase I trial of PG-11047 (formerly CGC-11047) in patients with advanced cancer. CellGate Inc., which was acquired by Progen in February, had enrolled a total of 31 patients before suspending the...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Company News

Cellgate, Progen deal

Progen acquired CellGate for about US$1.5 million in stock and up to US$19.5 million in milestones. Progen also will assume up to US$1 million of CellGate's debt. The deal gives Progen CGC-11047 , a polyamine...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Company News

Novacea management update

Novacea Inc. (NOVC), South San Francisco, Calif.   Business: Cancer, Hematology   Hired: Edward Schnipper as EVP and CMO, formerly president and CEO of CellGate Inc.  ...
08:00 , Jan 29, 2007 |  BioCentury  |  Product Development

Back-of-the-eye pipeline

Back-of-the-eye pipeline Back-of-the-eye pipeline Selected products in development for three major ophthalmic indications: diabetic macular edema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR). (A) In October, Eli Lilly (LLY) said it would appeal...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Clinical News

CGC-11047: Phase I started

Cellgate began an open-label, dose-escalation, U.S. Phase I trial in 15 patients who will receive CGC-11047 subconjunctivally. Cellgate Inc. , Redwood City, Calif.   Product: CGC-11047   Business: Ophthalmic   Molecular target: NA   Description:...
08:00 , Nov 6, 2006 |  BC Week In Review  |  Clinical News

CGC-11047: Phase II started

Cellgate began a Phase II trial in about 40 chemotherapy-naïve patients. Patients will receive 200 mg of IV CGC-11047 once-weekly for 3 weeks over a 4-week cycle. Cellgate Inc. , Redwood City, Calif.   Product:...
07:00 , Oct 9, 2006 |  BC Week In Review  |  Clinical News

CGC-11047: Phase Ib started

Cellgate began a dose-escalation Phase Ib trial in about 70 patients with advanced cell malignancies or lymphomas. The trial will measure the pharmacokinetics and anti-tumor activity of weekly IV doses of CGC-11047 over a 28-day...